
Lilly’s Kisunla Gets FDA Nod for Updated Label and Dosing in Early Alzheimer’s
FDA Greenlights Label Update and Revised Dosing Schedule for Lilly’s Kisunla (donanemab‑azbt) in Early Symptomatic Alzheimer’s Eli Lilly and Company today announced that the U.S. Food and Drug Administration (FDA)…












